Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > 60 to 1

<< Previous

Bullboard Posts

Next >>

Comment by regardlesson Mar 22, 2021 8:47pm

152 Views

Post# 32855738

RE:60 to 1

Well... it still has to be voted on and I doubt retailers are gonna vote for that andnim
sure any big bag holders in the 30-80 cent range may not either.../ this is brutal ... glad I only have 10 k into this piece of sht

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?